

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/584,304 Confirmation No.: 9013
Applicant : Bart STAELS
Filed : December 23, 2004
Title : METHOD FOR THE IDENTIFICATION OF COMPOUNDS
MODULATING REVERSE TRANSPORT OF CHOLESTEROL
TC/Art Unit : *Unassigned*
Examiner: : *Unassigned*
Docket No. : 67987.000004
Customer No. : **21967**

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RESPONSE TO NOTIFICATION TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir,

Responsive to the attached Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures ("Notice") mailed March 22, 2007, Applicant submits herewith a "Sequence Listing" believed to be in compliance with the requirements of 37 C.F.R. §§ 1.821-1.825. This response is filed within the two-month the period set for reply. Accordingly, no extensions of time or fees are believed necessary for entry and consideration of this response.

CONCLUSION


An indication of allowance of all claims is earnestly solicited. Early notification of a favorable consideration is respectfully requested.

It is believed that no fees are required with this submission. However, in the event that any fees are deemed necessary by the U.S. Patent and Trademark Office for entry of this response or to maintain this application as pending, please charge or credit any such variance to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Date: 4-19-07

By: 
Robert M. Schulman
Registration No. 31,196

Dana Z. Buschmann
Registration No. 54,567

HUNTON & WILLIAMS LLP
Intellectual Property Department
1900 K Street, N.W., Suite 1200
Washington, D.C. 20006-1109
(202) 955-1500 (telephone)
(202) 955-1939 (direct dial)
(202) 778-2201 (facsimile)

RMS/CJN/DZB:cdh/tmf



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/584,304	Bart Staels	67987.000004


INTERNATIONAL APPLICATION NO.	
PCT/FR04/03373	
I.A. FILING DATE	PRIORITY DATE
12/23/2004	12/23/2003

21967
HUNTON & WILLIAMS LLP
INTELLECTUAL PROPERTY DEPARTMENT
1900 K STREET, N.W.
SUITE 1200
WASHINGTON, DC 20006-1109

DOCKETED	3/27/07
ACTION CODE	SEQUENCE LISTING
DUE DATE	5-22-07
BASE DATE	3-22-07
DEADLINE	10-22-07
ATTORNEYS	RMS-AHS
INITIALS	B

CONFIRMATION NO. 9013

371 FORMALITIES LETTER



OC000000023019164

Date Mailed: 03/22/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

MAR 27 2007

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or

visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

JOHN L ANDERSON

Telephone: (703) 308-9140 EXT 211

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/584,304	PCT/FR04/03373	67987.000004

FORM PCT/DO/EO/922 (371 Formalities Notice)